http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2019342133-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2019-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12f7f1dd224d2fc32614a9f8bf2d8e96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_affd76d7c465fd8dc8814a97b511baca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3324e3986313c20bccf6e823a825a50d |
publicationDate | 2021-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2019342133-A1 |
titleOfInvention | Diagnostic methods for triple-negative breast cancer |
abstract | The invention provides methods and compositions for diagnosing and treating locally advanced or metastatic breast cancer (e.g., TNBC). The methods may include determining the presence and/or expression level of one or more of PD-L1, CD8, and/or stromal tumor- infiltrating lymphocytes (sTILs). Provided herein are methods for identifying a patient suffering from a locally advanced or metastatic TNBC who is likely to respond to treatment with an anti-cancer therapy that includes a PD-1 axis binding antagonist (e.g., an anti- PD-L1 antibody (e.g., atezolizumab) or an anti-PD-1 antibody) and a taxane (e.g., nab-paclitaxel or paclitaxel). Also provided are methods of selecting a therapy for a patient suffering from a locally advanced or metastatic TNBC. Further provided are methods of treating a patient suffering from locally advanced or metastatic TNBC. The methods may include administering a PD-1 axis binding antagonist (e.g., atezolizumab) and a taxane (e.g., nab-paclitaxel or paclitaxel) to the patient, for example, a patient identified as one who is likely to respond to the treatment. Also provided are pharmaceutical compositions for use in treating a patient suffering from locally advanced or metastatic TNBC. |
priorityDate | 2018-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1281.